Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Sacubitril and Valsartan Tablets, 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg (USRLD: Entresto tablets).
Sacubitril and valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalization.
The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India).
Powered by Capital Market – Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: Jul 10 2024 | 4:12 PM IST
